Semaglutide extends mouse lifespan beyond calorie restriction — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Semaglutide extended median lifespan by nearly 100 days in older female mice, with treatment beginning at 20 months of age and lasting until death.
- Danica Chen led a UC Berkeley research team that administered semaglutide to 20-month-old female mice for three months, observing improved muscle function, cognition, and blood sugar control.
- Calorie-restricted mice experienced metabolic slowdown over five months, while semaglutide-treated mice maintained stable metabolic rates despite similar food intake.
- Gene activity analysis revealed that semaglutide reduced inflammation and supported tissue repair mechanisms, indicating improvements in biological aging markers beyond those seen with diet alone.
- Rafael de Cabo commented that if GLP-1 agonists slow aging itself, the broad clinical benefits observed across conditions align with that mechanism.
- NIH’s National Institute on Aging supported the research through grants R01AG063404, R01AG063389, and R01AG082105, underscoring federal investment in aging-intervention science.
Why it matters: The finding that semaglutide extends lifespan beyond calorie restriction in mice shifts the focus from weight management to direct aging modulation, suggesting GLP-1 drugs could one day be repurposed for healthy aging in humans—potentially expanding their use to millions of older adults without obesity or diabetes.
Ask SkimNews
